Cargando…

Hybrid Tomo‐Helical and Tomo‐Direct radiotherapy for localized prostate cancer

PURPOSE: The aim of the study is to present a new planning approach to provide better planning target volume (PTV) coverage and reduce bladder and rectum dose with hybrid Tomo‐Helical (TH)/Tomo‐Direct (TD) radiotherapy (RT) for localized prostate cancer (LPC). METHODS: Twenty‐five LPC patients were...

Descripción completa

Detalles Bibliográficos
Autores principales: Karaca, Sibel, Koca, Timur, Sarpün, İsmail Hakkı, Tunçel, Nina, Korcum Şahin, Aylin Fidan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8504587/
https://www.ncbi.nlm.nih.gov/pubmed/34498363
http://dx.doi.org/10.1002/acm2.13406
_version_ 1784581348792467456
author Karaca, Sibel
Koca, Timur
Sarpün, İsmail Hakkı
Tunçel, Nina
Korcum Şahin, Aylin Fidan
author_facet Karaca, Sibel
Koca, Timur
Sarpün, İsmail Hakkı
Tunçel, Nina
Korcum Şahin, Aylin Fidan
author_sort Karaca, Sibel
collection PubMed
description PURPOSE: The aim of the study is to present a new planning approach to provide better planning target volume (PTV) coverage and reduce bladder and rectum dose with hybrid Tomo‐Helical (TH)/Tomo‐Direct (TD) radiotherapy (RT) for localized prostate cancer (LPC). METHODS: Twenty‐five LPC patients were included in this retrospective study. TH plans, TD plans, and hybrid TH/TD plans were created. Lateral beams were used for the hybrid TD plan and the prescribed dose was 70 Gy in 28 fractions (hybrid plans were combined 45 Gy/ 18 fxs for TH and 25 Gy/10 fxs for TD). Doses of PTV (D2%, D98%, D50%, homogeneity index (HI), conformity index (CI), coverage) and organs at risk (OARs) (V50%, V35%, V25%, V5%, and V95%) were analyzed. The Wilcoxon signed‐rank test was used to analyze the difference in dosimetric parameters. p‐Value < 0.05 was considered statistically significant. RESULTS: TH plans showed better CI, and target coverage (p < 0.01) than TD and hybrid plans in all patient plan evaluations. However, TD plans D2%, D98%, and D50% doses were better than TH and hybrid plans. The HI values were similar between the three plans. Significant reductions in bladder and rectum V50%, V35%, and V25% doses (p < 0.001) were observed with hybrid plans compared to TH and TD. Penile bulb V95% and bowel V5% doses were better in the hybrid plans. Left and right femoral head V5% doses were higher in the hybrid plan compared to others (p < 0.001). CONCLUSION: Concurrently hybrid TH/TD RT plan can be a good option to reduce the doses of the rectum and bladder in the RT of LPC.
format Online
Article
Text
id pubmed-8504587
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-85045872021-10-18 Hybrid Tomo‐Helical and Tomo‐Direct radiotherapy for localized prostate cancer Karaca, Sibel Koca, Timur Sarpün, İsmail Hakkı Tunçel, Nina Korcum Şahin, Aylin Fidan J Appl Clin Med Phys Radiation Oncology Physics PURPOSE: The aim of the study is to present a new planning approach to provide better planning target volume (PTV) coverage and reduce bladder and rectum dose with hybrid Tomo‐Helical (TH)/Tomo‐Direct (TD) radiotherapy (RT) for localized prostate cancer (LPC). METHODS: Twenty‐five LPC patients were included in this retrospective study. TH plans, TD plans, and hybrid TH/TD plans were created. Lateral beams were used for the hybrid TD plan and the prescribed dose was 70 Gy in 28 fractions (hybrid plans were combined 45 Gy/ 18 fxs for TH and 25 Gy/10 fxs for TD). Doses of PTV (D2%, D98%, D50%, homogeneity index (HI), conformity index (CI), coverage) and organs at risk (OARs) (V50%, V35%, V25%, V5%, and V95%) were analyzed. The Wilcoxon signed‐rank test was used to analyze the difference in dosimetric parameters. p‐Value < 0.05 was considered statistically significant. RESULTS: TH plans showed better CI, and target coverage (p < 0.01) than TD and hybrid plans in all patient plan evaluations. However, TD plans D2%, D98%, and D50% doses were better than TH and hybrid plans. The HI values were similar between the three plans. Significant reductions in bladder and rectum V50%, V35%, and V25% doses (p < 0.001) were observed with hybrid plans compared to TH and TD. Penile bulb V95% and bowel V5% doses were better in the hybrid plans. Left and right femoral head V5% doses were higher in the hybrid plan compared to others (p < 0.001). CONCLUSION: Concurrently hybrid TH/TD RT plan can be a good option to reduce the doses of the rectum and bladder in the RT of LPC. John Wiley and Sons Inc. 2021-09-08 /pmc/articles/PMC8504587/ /pubmed/34498363 http://dx.doi.org/10.1002/acm2.13406 Text en © 2021 The Authors. Journal of Applied Clinical Medical Physics published by Wiley Periodicals, LLC on behalf of The American Association of Physicists in Medicine https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Radiation Oncology Physics
Karaca, Sibel
Koca, Timur
Sarpün, İsmail Hakkı
Tunçel, Nina
Korcum Şahin, Aylin Fidan
Hybrid Tomo‐Helical and Tomo‐Direct radiotherapy for localized prostate cancer
title Hybrid Tomo‐Helical and Tomo‐Direct radiotherapy for localized prostate cancer
title_full Hybrid Tomo‐Helical and Tomo‐Direct radiotherapy for localized prostate cancer
title_fullStr Hybrid Tomo‐Helical and Tomo‐Direct radiotherapy for localized prostate cancer
title_full_unstemmed Hybrid Tomo‐Helical and Tomo‐Direct radiotherapy for localized prostate cancer
title_short Hybrid Tomo‐Helical and Tomo‐Direct radiotherapy for localized prostate cancer
title_sort hybrid tomo‐helical and tomo‐direct radiotherapy for localized prostate cancer
topic Radiation Oncology Physics
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8504587/
https://www.ncbi.nlm.nih.gov/pubmed/34498363
http://dx.doi.org/10.1002/acm2.13406
work_keys_str_mv AT karacasibel hybridtomohelicalandtomodirectradiotherapyforlocalizedprostatecancer
AT kocatimur hybridtomohelicalandtomodirectradiotherapyforlocalizedprostatecancer
AT sarpunismailhakkı hybridtomohelicalandtomodirectradiotherapyforlocalizedprostatecancer
AT tuncelnina hybridtomohelicalandtomodirectradiotherapyforlocalizedprostatecancer
AT korcumsahinaylinfidan hybridtomohelicalandtomodirectradiotherapyforlocalizedprostatecancer